Cancer

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations,...

At 2025 STAT Summit, Guests including Joe Kennedy III, AMA President, Former NIH Leaders, Explore CRISPR, Pharma, Public Health, and More

BOSTON, Oct. 17, 2025 /PRNewswire/ -- The seventh annual STAT Summit kicked off Wednesday in Boston, bringing together a carefully curated...

Nabsys Presents Data Detailing OhmX™ Platform’s Unique Advantages of Genome Mapping at American Society of Human Genetics (ASHG) 2025 Annual Meeting

Electronic genome mapping (EGM) detects and validates structural variants in cancer genomes with improved accuracy over existing platforms, including optical...

Nabsys Presents Novel Disease Insights and Advantages in Structural Variant Detection using OhmX™ Platform at American Society of Human Genetics (ASHG) 2025 Annual Meeting

Multi-omics study utilizing electronic genome mapping (EGM) reveals 70% of patients with interstitial cystitis/bladder pain syndrome (IC/BPS) have psychiatric comorbidities...

Eon Further Establishes Leadership Position in Early Detection and Management of Incidental Findings, Announces Half a Billion Radiology Reports Analyzed

Specialized clinical AI and extensive real-world experience enable early diagnosis across 75+ health systems DENVER, Oct. 16, 2025 /PRNewswire/ -- Eon,...

A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan

ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH),...

Genomics launches Mystra: the world’s first and original AI-enabled human genetics platform, now available to transform drug target discovery and clinical development

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes,...

error: Content is protected !!